Resources
Downloads
Managed Care Marketing
To learn more about our unique approach to advisory meetings, download Mark Zitter’s article “The State of the Art in Advisory Meetings” from Pharmaceutical Executive.
Want help navigating the managed care market? Download our Managed Care Strategy Checklist – a basic tool to help you ask the right questions to better plan your managed care approach.
Still think that if you’ve seen one managed care organization, you’ve seen one managed care organization? We’ve developed a proprietary approach to market segmentation that delivers real results. To learn more, download this white paper.
With the advent of Medicare Part D, the majority of pharmaceutical products are now reimbursed under an insurance arrangement. For manufacturers, this necessitates a re-thinking of the importance of the health plan Pharmacy and Therapeutics (P&T) Committee review. Now more than ever before, manufacturers need to consider the P&T review in the marketing plans for both marketed and pre-launch products. This free white paper presents a series of case studies in order to illustrate the various ways P&T committees make formulary coverage decisions. The article also provides advice on how to overcome several common obstacles your product may face when reviewed by the P&T committee.
Biotechnology and Managed Care
Managed care organizations continue to grow more sophisticated in their management of biotechnology products. For a detailed analysis of the evolution of managed care’s approach to specialty products, download Tom Baker’s article “5 Stages of Biotechnology Management” from the February 2005 issue of Biotechnology Healthcare.
To review some of our research findings from the biotechnology market, download Tom Baker’s article “Specialty Therapies Lose Special Status” from the September 2004 issue of Pharmaceutical Executive.
The Changing Management of Oncology Medicine
For a long time oncology has been a third rail for managed care organizations, but that has begun to change. Recent primary research finds that Medicare reform, greater payer oversight of specialty and biologic therapies, and the growing technological sophistication of the therapies themselves have combined to create an unprecedented opportunity for greater payer management of this traditionally autonomous category.